Everyone knows aspirin. It’s been around for over a century…

Bayer commercialized aspirin in the late 1800s. And the drug helped it grow into a $64 billion pharmaceutical giant.

But what most people don’t know is that aspirin’s active ingredient comes from the willow tree. People have brewed its bark to make pain-relieving teas since ancient times.

You can still buy a bottle of 100 white willow bark pills for under $6 on Amazon. (A similar-sized bottle of Bayer Extra Strength aspirin costs twice as much.)

Let me ask you a question…

When was the last time you bought white willow bark pills? Rarely – if ever – right? And yet it’s 50% cheaper than aspirin.

Yet, Bayer-branded aspirin is the most popular aspirin pill in the world.

Here’s why that matters to you…

White willow bark is a natural compound. So you can’t patent it. And if you can’t patent it, anyone can sell it. So if you can’t patent it, how did Bayer parlay its aspirin brand into a $64 billion pharma giant?

Simple. It found a way to patent the un-patentable.

The company realized if it could synthesize aspirin in a lab, then it could patent it. And on March 6, 1899, that is exactly what it did. More than a century later… Bayer still dominates the aspirin market.

That’s the power of being first.

Here’s why I’m telling you this…

I’ve found a company using the same “synthetic” playbook to patent what could be the biggest cure-all drug the world has ever seen.

Just like how aspirin is used to treat a myriad of ailments such as heart disease, arthritis, and inflammation… this drug has wide applications across hundreds of ailments.

And I believe it has the potential to make you at least a 30x-plus return.

The Hottest Sector in America

The IPO market is on fire right now. In fact, Bloomberg reports that “red-hot IPOs are creating a new billionaire every week.”

An IPO – or initial public offering – is when a private company lists on a public exchange. And so far this year, we’ve seen huge gains on IPO day.

Companies like Jamf, BigCommerce, and Lemonade have made 51%, 201%, and 139%, respectively, on their IPO days this year.

Now, one of the hottest sectors in this red-hot market is biotech/biopharma.

In the second half of 2020, we’ve seen more than 240 IPOs so far. Nearly half of them have come from biotech/biopharma.

According to research firm Pitchbook, venture capitalists have raised over $5.5 billion for biopharma companies in Q2 2020. It’s their largest quarter in history.

Already, we’ve seen biotech IPOs like Inovio Pharmaceuticals, Moderna, and Seres Therapeutics soar 131%, 126%, and 693%, respectively.

Long story short… the market is red-hot for biotech IPOs. But instead of buying in at the IPO price, I’ve found one you can buy into at the pre-IPO price.

As I explained last week, pre-IPO shares are much cheaper than IPO shares.

How much cheaper? Well, when eBay went public, its IPO shares sold at $18. But pre-IPO shares went for just 11 cents.

That’s not a typo. Pre-IPO buyers got in for as little as 11 cents per share. Because of those big discounts, pre-IPO investors are making vast fortunes while uninformed IPO investors are getting peanuts.

Here’s the proof…

In 2020, the average pre-IPO deal has returned over 22,000% on its first day as a public company.

But if you had waited and didn’t get in until the IPO shares became available… that 22,000% return shrinks to just 36%. Think about that.

That’s the penalty for not taking action right now.

You can see the difference. One changes your life forever, and the other does nothing for you.

So you can see if you’re not in before the IPO, you’re losing out on what could be life-changing profits.

And that’s why I’m writing to you today.

One Day Away From a Lifetime of Financial Security

Like willow bark, the plant this company synthesized has plenty of therapeutic properties.

Millions of people already use a naturally occurring version of this compound to alleviate joint pain, arthritis, epilepsy, anxiety, and countless other ailments.

The company we’ve found is synthesizing compounds from this plant… patenting the new form… and bottling it to treat diseases like multiple sclerosis.

And the Food and Drug Administration (FDA) has granted this compound “orphan drug status.” Those three words – “orphan drug status” – are huge.

That means the company will have a seven-year monopoly to sell the drug.

Just how valuable is a seven-year monopoly? Bayer is still the No. 1 seller of aspirin, and its patent ran out over 100 years ago. That’s the power of being first.

You create a money machine that can last over a century. One investment like that can set you and your family up for life.

That’s the power of getting in the right deal at the right time with an exclusive monopoly.

Our research suggests a 30x return could be a very low estimate. High-side projections suggest we could see gains as big as 50x.

Here’s the catch: I don’t know how long this opportunity will last or if it’s even right for you. That’s why I put together a special presentation on this idea so you can make up your own mind.

So if you want more details, click here to watch a special report I put together that will tell you all about how this opportunity works and how you can get involved.

Let the Game Come to You!

Teeka Tiwari
Editor, Palm Beach Daily

P.S. This idea is more urgent than you may think. You see, pre-IPO deals have strict limits on how much capital they can raise. And the ceiling on this deal is filling up quickly.

I can’t promise it’ll be open past today. So click here now to learn more